JP7888216B2 - Muc1-c/細胞外ドメイン(muc1-c/ecd)に対する抗体 - Google Patents

Muc1-c/細胞外ドメイン(muc1-c/ecd)に対する抗体

Info

Publication number
JP7888216B2
JP7888216B2 JP2023502897A JP2023502897A JP7888216B2 JP 7888216 B2 JP7888216 B2 JP 7888216B2 JP 2023502897 A JP2023502897 A JP 2023502897A JP 2023502897 A JP2023502897 A JP 2023502897A JP 7888216 B2 JP7888216 B2 JP 7888216B2
Authority
JP
Japan
Prior art keywords
antibody
cells
seq
muc1
cancer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023502897A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023534959A (ja
JP2023534959A5 (cg-RX-API-DMAC7.html
Inventor
スレンダー カルバンダ
ドナルド ダブリュ. キーフ
Original Assignee
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド
エックスワイワン セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド, エックスワイワン セラピューティクス インコーポレイテッド filed Critical デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド
Publication of JP2023534959A publication Critical patent/JP2023534959A/ja
Publication of JP2023534959A5 publication Critical patent/JP2023534959A5/ja
Application granted granted Critical
Publication of JP7888216B2 publication Critical patent/JP7888216B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
JP2023502897A 2020-07-16 2021-07-15 Muc1-c/細胞外ドメイン(muc1-c/ecd)に対する抗体 Active JP7888216B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063052599P 2020-07-16 2020-07-16
US63/052,599 2020-07-16
PCT/US2021/070881 WO2022016190A1 (en) 2020-07-16 2021-07-15 Antibodies against the muc1-c/extracellular domain (muc1-c/ecd)

Publications (3)

Publication Number Publication Date
JP2023534959A JP2023534959A (ja) 2023-08-15
JP2023534959A5 JP2023534959A5 (cg-RX-API-DMAC7.html) 2024-06-07
JP7888216B2 true JP7888216B2 (ja) 2026-07-13

Family

ID=79554266

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023502897A Active JP7888216B2 (ja) 2020-07-16 2021-07-15 Muc1-c/細胞外ドメイン(muc1-c/ecd)に対する抗体

Country Status (11)

Country Link
US (1) US20230265208A1 (cg-RX-API-DMAC7.html)
EP (1) EP4182354A4 (cg-RX-API-DMAC7.html)
JP (1) JP7888216B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230116767A (cg-RX-API-DMAC7.html)
CN (1) CN117693530A (cg-RX-API-DMAC7.html)
AU (1) AU2021310499A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023000728A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186181A1 (cg-RX-API-DMAC7.html)
IL (1) IL299903A (cg-RX-API-DMAC7.html)
MX (1) MX2023000784A (cg-RX-API-DMAC7.html)
WO (1) WO2022016190A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4676975A1 (en) * 2023-03-03 2026-01-14 Beone Medicines I GmbH Muc1 and cd16a antibodies and methods of use
TW202436357A (zh) * 2023-03-03 2024-09-16 瑞士商百濟神州瑞士有限責任公司 Muc1抗體及使用方法
WO2025217515A2 (en) 2024-04-12 2025-10-16 Dana-Farber Cancer Institute, Inc. Identification of muc1-c as a target for the treatment of squamous cell carcinomas
KR20260100547A (ko) * 2024-12-20 2026-06-30 주식회사 펩트론 항-muc1 항체를 포함하는 면역 항암 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017505625A (ja) 2014-01-29 2017-02-23 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Muc1−c/細胞外ドメイン(muc1−c/ecd)に対する抗体
US20180036441A1 (en) 2016-08-05 2018-02-08 Dana-Farber Cancer Institute, Inc. Antibodies against the muc1-c/extracellular domain (muc1-c/ecd)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2601417C (en) * 2004-07-01 2018-10-30 Novo Nordisk A/S Human anti-kir antibodies
JP2012504961A (ja) * 2008-10-06 2012-03-01 ミネルバ バイオテクノロジーズ コーポレーション Muc1*抗体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017505625A (ja) 2014-01-29 2017-02-23 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Muc1−c/細胞外ドメイン(muc1−c/ecd)に対する抗体
US20180036441A1 (en) 2016-08-05 2018-02-08 Dana-Farber Cancer Institute, Inc. Antibodies against the muc1-c/extracellular domain (muc1-c/ecd)

Also Published As

Publication number Publication date
JP2023534959A (ja) 2023-08-15
CN117693530A (zh) 2024-03-12
BR112023000728A2 (pt) 2023-03-21
US20230265208A1 (en) 2023-08-24
WO2022016190A1 (en) 2022-01-20
AU2021310499A1 (en) 2023-03-09
CA3186181A1 (en) 2022-01-20
EP4182354A1 (en) 2023-05-24
KR20230116767A (ko) 2023-08-04
MX2023000784A (es) 2023-04-18
IL299903A (en) 2023-03-01
EP4182354A4 (en) 2024-12-25

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230816

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240529

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260519

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260601

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260624

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260629

R150 Certificate of patent or registration of utility model

Ref document number: 7888216

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150